153 results about "Cancer gene" patented technology

The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides gene expression profiles associated with solid tumor stem cells, as well as novel stem cell cancer gene signatures useful for the diagnosis, characterization, prognosis and treatment of solid tumor stem cells.

The present invention provides a bacterium belonging to the genus Bifidobacterium, by which DNA coding for a protein having an antitumor activity or DNA coding for a protein having the activity of converting a precursor of an antitumor substance into the antitumor substance is delivered to tumor tissues specifically under anaerobic conditions thereby expressing the protein encoded by the DNA, as well as a pharmaceutical composition comprising said anaerobic bacterium.

The invention relates to a CRISPR/Cas9 enrichment sequencing method applied in large-scale screening of cancer genes. Firstly, an sgRNA library is established; then the sgRNA library is packaged by lentiviruses, and viruses are collected; the sgRNA library is screened in a cancer cell line, the obtained cells are extracted and screened, and genome DNAs of precancerous cells are screened; finally, enrichment of sgRNAs in the genome DNAs is carried out. When the provided method is compared with the prior art, the screening process of CRISPR/Cas9 cells is improved, the virus infection efficiency is determined and the virus MOI value is determined through a simple method and by utilization of puromycin resistance of infected cells, importantly, the restriction enzyme cutting method and a high flux method are combined, correct chromatin fragments can be obtained effectively, false positive caused by non-specific PCR amplification can be lowered, a DNA template of sgRNAs can be amplified efficiently, and a library establishment efficiency is raised.

The invention relates to a method for applying a functionalized poly(amidoamine) dendrimer and a nanometer compound thereof in gene transfection. The method comprises the following steps: preparation of the functionalized poly(amidoamine) dendrimer and the nanometer compound thereof, surface functional modification and characterization; preparation of functionalized poly(amidoamine) dendrimer-nanometer compound/pDNA; and research on gene transfection efficiency of the functionalized poly(amidoamine) dendrimer-nanometer compound/pDNA. The advantages of easy operation, simple transfection conditions, high transfection efficiency, strong specificity and the like are obtained in application of the functionalized poly(amidoamine) dendrimer and the nanometer compound thereof in gene transfection, and the functionalized poly(amidoamine) dendrimer and the nanometer compound thereof have good application prospects in aspects like gene therapy of cancers.

The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides gene expression profiles associated with solid tumor stem cells, as well as novel stem cell cancer gene signatures useful for the diagnosis, characterization, prognosis and treatment of solid tumor stem cells.

The invention discloses a differentially expressed gene identification method based on combined constraint non-negative matrix factorization. The method comprises the following steps of 1, representing a cancer-gene expression data set with a non-negative matrix X, 2, constructing a diagonal matrix Q and an element-full matrix E, 3, introducing manifold learning in the classical non-negative matrix factorization method, conducting orthogonal-constraint sparseness and constraint on a coefficient matrix G, and obtaining a combined constraint non-negative matrix factorization target function, 4, calculating the target function, and obtaining iterative formulas of a basis matrix F and the coefficient matrix G, 5, conducting semi-supervision non-negative matrix factorization on the non-negative data set X, and obtaining the basis matrix F and the coefficient matrix G after iteration convergence, 6, obtaining an evaluation vector (the formula is shown in the description), sorting elements in the evaluation vector (the formula is shown in the description) from large to small according to the basis matrix F, and obtaining differentially expressed genes, 7, testing and analyzing the identified differentially expressed genes through a GO tool. The identification method can effectively extract the differentially expressed genes where cancer data is concentrated, and be applied in discovering differential features in a human disease gene database. The identification method has important clinical significance for early diagnosis and target treatment of diseases.

Molecular displacement label sequence parallel inspection - oligonucleo coded label molecular pool micro-ball array analysis includes: using artificial sequential oligo nucleo-labeled DNA coded molecular pool, coating micro-balls with ligands in correspondent pools to form catching micro-balls, caught ligands combined with labeled ciding molecular pools to form labeled micro-balls array pools. Sample molecules competitively combined with micro-balls catching ligands when sample contains molecules same as those in labeled micro-balls array pools, calculating amount of displaced coded molecular sequence computing kinds and mounts of molecules to be tested. It verifies high flux of inspection with good repeatability, high reliability and sensitivity, so that it is suitable to precisely parallel quantitative analysis concerned with cancer-inhibiting genes and cancer genes pools, cell factor pools, etc.

A method and biosensor device for detecting single strand target nucleic acid by cyclic voltammetry is described. A porous silicon chip is linked to bound DNA probe complementary to the target nucleic acid. The device is particularly useful for detecting microorganisms and viruses that may be pathogenic or cancer genes, however any target nucleic acid can be detected by using a specific DNA probe.

The invention discloses a method for identifying a cancer molecular subtype based on a spectral clustering algorithm of a sparse similar matrix. The method is characterized in that based on the spectral clustering algorithm of the sparse similar matrix, a cancer molecular subtype prediction model is built by utilizing cancer gene expression profile data as a training set sample; and the prediction model is used for predicting a cancer modular subtype of an independent test set sample, and a cancer sample set is divided into multiple types of molecular subtypes. According to the method, various patients with different prognosis effects are effectively distinguished for high heterogeneity of cancer molecular expression level, and different individual treatment schemes can be made for various cancer patients respectively.

The invention relates to a preparation method of tetra-palladium complexes in a crossed structure which synthesize tetrapyridylporphine bridge by using supramolecular self-assembly. The tetra-palladium complexes are possibly used for treating human cancers. The MTT experiment data indicates that the compounds have high antitumor activity. A single-teeth platinum ligand, of which the chloride ion is substituted by nitrate, and a bridging ligand tetrapyridylporphine are subjected to self-assembly, thereby obtaining new potential anticancer drugs with excellent anticancer activity and tumor targeting property. The complexes have excellent tumor cell targeting property, and induce the G-rich sequence of the cancer gene to form a G-quadruplex structure, thereby inhibiting the activity of the telomere enzyme and further having high antitumor activity. In addition, since the preparation method is simple and easy to implement, has lower cost, and can be complemented in a common chemical laboratory, and does not have environment pollution in the production process. Therefore, the tetrapyridylporphine bridged tetra-palladium complexes in a crossed structure can be used as novel potential antineoplastic drugs.

The invention discloses pharmaceutical application of tauroursodeoxycholic acid and acceptable salts thereof. The tauroursodeoxycholic acid can reduce the expression and activity of cancer genes Yap and inhibit the activity of a UPR (unfolded protein response) signal channel component; and as verified in two liver cancer models with Yap activation and UPR signal channel activation functions, the tauroursodeoxycholic acid has an effect of preventing and treating a liver cancer, and has a certain application prospect in preparation of a medicament for preventing and treating the liver cancer, particularly in preparation of a medicament for preventing and treating the liver cancer caused by Yap activation or UPR signal channel activation.

The invention discloses a cancer gene expression profile data identification method based on integration of extreme learning machines. The method includes the steps of selection and integration of member extreme learning machines (ELMs). The method concretely includes the steps that preprocessing is carried out on a cancer gene expression profile data set, wherein the preprocessing includes gene selection and normalization of expression profile data; N sample sets are generated through a Bagging method, and each sample set is divided into a training set and a verification set according to a certain proportion; N ELMs are generated on the N training sets in a learning mode, and L ELMs (L&1t; N) with the highest recognition rate on the corresponding verification sets are selected to form an alternative member ELM base; K member ELMs (K&1t; L) forming an integrated system are selected from L ELMs based on the particle swarm optimization algorithm; the integrated vote weight of K member ELMs is worked out by utilizing the minimum-norm least square method; an integrated ELM system is obtained, and the integrated ELM system is used for performing tumor recognition on a newly increased cancer gene expression profile sample. Through the method, the cancer gene expression profile data can be quickly and accurately recognized.

The invention provides a method for preparing chorionic mesenchymal stem cells. The method comprises the following steps: performing aseptic collection of placentas; separating chorionic tissues; acquiring chorionic mesenchymal stem cells; culturing the chorionic mesenchymal stem cells; performing frozen preservation on the chorionic mesenchymal stem cells; and reviving the chorionic mesenchymal stem cells. The method provided by the invention has the following technical effects: by adopting a pollution prevention method to reduce the probability of pollution from sources, the probability of pollution is effectively reduced by flushing a surface for multiple times; the pollution of hybrid cells is reduced; a single enzyme is adopted for digestion, thereby simplifying the process; the use of animal source components is reduced by using a serum-free culture medium for culture, the cell performance is stable, the in vitro long-term cultivation of the chorionic mesenchymal stem cells can be maintained, the form, proliferation ability, MSC surface marker expression and differentiation ability of the cells are maintained, and the expression of telomerase, the stable expression of cancer genes and the stable karyotype are maintained; and the enzyme digestion, frozen preservation and reviving cause no damage to the cells.

Mutant epitopes encoded by cancer genes are virtually always located in the interior of cells, making them invisible to conventional antibodies. We generated single chain variable fragments (scFvs) specific for mutant peptides presented on the cell surface by human leukocyte antigen (HLA) molecules. These scFvs can be converted to full-length antibodies, termed MANAbodies, targeting “Mutation Associated Neo-Antigens” bound to HLA. A phage display library representing a highly diverse array of single-chain variable fragment sequences was first designed and constructed. A competitive selection protocol was then used to identify clones specific for peptides bound to pre-defined HLA types. In this way, we obtained scFvs, including one specific for a peptide encoded by a common KRAS mutant and another by a common EGFR mutant. Molecules targeting MANA can be developed that specifically react with mutant peptide-HLA complexes even when these peptides differ by only one amino acid from the normal, wild-type form.

The invention discloses an amino acid sequence for detecting a tumor marker P16 antigenic epitope and application of the amino acid sequence, and belongs to the technical field of immunology. The invention provides an antigenic amino acid sequence of a tumor anti-cancer gene P16. The P16 polypeptide antigen is used for detecting corresponding specific antigenic epitope in the blood of a patient with lung cancer and esophagus cancer; the antigenic epitope can be used as a tumor marker for estimating the degree of risk for occurring the lung cancer and the esophagus cancer. And the antigenic polypeptide and an antibody thereof can be used for preparing tumor early-diagnosis reagent and developing a targeted drug for treating the tumors.

The invention discloses a siRNA-loading nanoparticle. The siRNA is loaded in a duct of mesoporous carbon dioxide through a nonelectrostatic effect, an electropositive high molecule is wrapped on the surface and high molecular polyethylene glycol with biocompatibility and a polypeptide molecule which modifies a transcellular membrane and an lysosome-breaking membrane are connected, so that the nanoparticle has good biocompatibility and the interference effect of the siRNA is improved. The interference effect of the siRNA is remarkably stronger than that of a commercial lipidosome. The nanoparticle has a wide prospect in preparation of cancer gene therapeutic drugs.

The invention discloses a probe for detecting a circulating tumor DNA (Deoxyribonucleic Acid) of a human breast cancer and application of the probe, belonging to the field of diagnosis and prevention of diseases. The invention designs a breast cancer selector which consists of DNA segments in mutation regions of related genes of the breast cancer. The circulating tumor DNA (ctDNA) of a breast cancer patient is subjected to liquid-phase hybridization capture by using the probe designed by the selector; after high-throughput sequencing, specific cancer gene variation of a patient is found, and a tumor load is monitored. Compared with a conventional detection means, the probe and the application thereof disclosed by the invention have the characteristics of no invasiveness, high throughout, good sensitivity and specificity, and the like; the probe and the application thereof can be used for better screening and early-stage diagnosis of the human breast cancer and are applied to individualized treatment of cancer.

The invention discloses a method for establishing a tree-shrew breast cancer model for slow virus by nipple injection. Slow virus is introduced to a tree-shrew breast duct by adopting a nipple injection technology, so that a cancer gene is over-expressed or an anti-cancer gene is knocked down after epithelial cells in a mediated duct are infected, and therefore, tree-shrew breast tumors are induced. According to the method for establishing a tree-shrew breast cancer model for slow virus by nipple injection disclosed by the invention, the breast tumors can be touched within two weeks after expressing the cancer gene PyMT; and moreover, the induction success rate is almost 100%, and the method is short in incubation period, strong in specificity, extremely high in induction rate, stable and convenient and simple to operate. The method disclosed by the invention can be used for quickly and efficiently establishing the tree-shrew breast cancer model.

The invention belongs to the filed of microorganism animal cell lines and provides a Chinese lung adenocarcinoma cell line with high metastases potentiality of bone, lever and adrenal gland. According to the invention, hydrothorax of an adenocarcinoma first-diagnosis patient is used as primary culture of cells; the human adenocarcinoma cell has the preservation number of CGMCC No.3137 and classified name as human lung adenocarcinoma cell line CPA-Yang3, can grow adhered to the wall and has the tumorigenesis rate up to 100 percent; the human lung adenocarcinoma cell can grow quickly and metabolize vigorously; the expression levels of cancer genes EMS1, VEGF-C, IL-6, IL-8, SVIL and AR gene are higher than the expression level of SPC-A-1 cell; and the lung adenocarcinoma cancel cell has the biological characteristics of mainly transferring the bone and having high transfer potential of the lever and the adrenal gland, high growth speed of bone transfer cells and complete cell morphology. The invention can be used for providing reference data to early diagnosis for transferring the human lung adenocarcinoma bone, further establishing the relevant gene chip technology and assessing and exploring the curative effects of various medicaments and the like by comprehensively applying the gene chip, quantifying PCR (Polymerase Chain Reaction), western blot in real time and other technologies.

The invention belongs to the technical field of biology, and particularly discloses a capture sequencing probe and application thereof. The capture sequencing probe comprises at least one nucleotide sequence selected from the following nucleotide sequences: SEQIDNO: 1-2909. A method for capturing the sequencing probe in rectal cancer gene sequencing comprises the following steps: extracting DNA double-stranded nucleic acid; carrying out denaturation treatment on the DNA double-stranded nucleic acid to obtain a DNA single strand, and capturing the DNA single strand by using the capture probe; and carrying out computer sequencing on the captured DNA single strand to obtain a nucleic acid sequence in tumor tissues. The invention also discloses a kit which comprises the capture sequencing probe. The invention also discloses application of the kit in capturing a target sequence of a genome related to individualized medication of colorectal cancer. The capture probe can efficiently and completely capture the critical region of the colorectal cancer genome, obviously enhances the sequencing depth, greatly lowers the detection cost and sequencing data quantity, shortens the single sample analysis time, and meets the individualized user demands.